Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | LTK | P29376 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | CDK8 | P49336 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11275010 | 0.82 | ALDH1A1 (0.47) | KDM4EHPGDLMNAL3MBTL1MAPK1 | |
| SCHEMBL31133143 | 0.81 | NPSR1 (0.43) | KDM4EHPGDLMNADAPK3PRKD3 | |
| SCHEMBL729060 | 0.81 | L3MBTL1 (0.46) | KDM4EHPGDLMNAL3MBTL1KMT2A | |
| SCHEMBL21057401 | 0.80 | CYP1A2 (0.36) | KDM4EHPGDDAPK3PRKD3MAP4K4 | |
| SCHEMBL25759724 | 0.79 | SMN1; SMN2 (0.50) | KDM4ELMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL9194890 | 0.79 | KDM4E (0.42) | KDM4EHPGDLMNAL3MBTL1KMT2A | |
| SCHEMBL6996899 | 0.79 | NPSR1 (0.36) | KDM4EHPGDDAPK3PRKD3MAP4K4 | |
| SCHEMBL6363938 | 0.79 | KDM4E (0.44) | KDM4ELMNADAPK3PRKD3MAP4K4 | |
| SCHEMBL1095 | 0.79 | PIM3 (0.49) | KDM4ELMNADAPK3PRKD3MAP4K4 | |
| SCHEMBL24276004 | 0.78 | MAPK1 (0.40) | KDM4EHPGDLMNADAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002380-A1 | REV-ERB AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4228632-A2 | REV-ERB AGONISTS | Saint Louis University (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116635029-A | REV-ERB agonists | 圣路易斯大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022093552-A9 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022093552-A9 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022093552-A2 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093552-A2 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-07-19 | — | — | US | disclosed |
| US-9969748-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | disclosed |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| EP-3157923-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193168-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| US-4317823-A | FOR TREATMENT OF GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | KDM4E 1191/4885HPGD 4029/4885LMNA 4764/4885 |
| US-20240002380-A1 | REV-ERB AGONISTS | NR1D1, ESRRA, ESRRB | KDM4E 1855/4885HPGD 2240/4885LMNA 1829/4885 |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | KDM4E 1191/4885HPGD 4029/4885LMNA 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.